Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001666

Progesterone for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Progesterone, 4-Pregnene-3,20-dione

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H30O2
CAS Number:
57-83-0
Molecular Weight:
314.46
Beilstein/REAXYS Number:
1915950
MDL number:
MFCD00003658
UNSPSC Code:
41116107
PubChem Substance ID:
329831529
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

progesterone

manufacturer/tradename

EDQM

mp

128-132 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

InChI key

RJKFOVLPORLFTN-LEKSSAKUSA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Progesterone for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Induces maturation and secretory activity of the uterine endothelium; suppresses ovulation. Progesterone is implicated in the etiology of breast cancer.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Steroid hormone produced by the corpus luteum.
Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1142

Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material

1568007

Progesterone, United States Pharmacopeia (USP) Reference Standard

P3300000

Progesterone, European Pharmacopoeia (EP) Reference Standard

Y0001665

Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001667

Progesterone for impurity H identification, European Pharmacopoeia (EP) Reference Standard

BP449

Progesterone, British Pharmacopoeia (BP) Reference Standard

PHR2280

Progesterone Impurity J, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8932

(20R)-20-Hydroxypregn-4-en-3-one, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8933

(17α)-Pregn-4-ene-3,20-dione, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8935

(20S)-20-Hydroxypregn-4-en-3-one, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8939

(20R)-3-Oxopregn-4-en-20-yl acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8943

(20S)-3-Oxopregn-4-en-20-yl acetate

PHR2905

Progesterone Related Compound H, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gunter von Minckwitz et al.
The Lancet. Oncology, 15(7), 747-756 (2014-05-06)
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy
Yanping Kuang et al.
Reproductive biomedicine online, 29(6), 684-691 (2014-12-03)
Previous studies have shown that existing antral follicles in the luteal phase enable ovarian stimulation. In a pilot study, the efficacy of double stimulations during the follicular and luteal phases in women with poor ovarian response was explored (defined according
Brett E Skolnick et al.
The New England journal of medicine, 371(26), 2467-2476 (2014-12-11)
Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. We investigated the efficacy and safety of progesterone in a large, prospective, phase
Eszter Papp et al.
The Journal of infectious diseases, 211(1), 10-18 (2014-07-18)
Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age (SGA) births. The mechanisms underlying these
A R Harmer et al.
The Journal of physiology, 592(3), 523-535 (2013-12-04)
Calcium cycling is integral to muscle performance during the rapid muscle contraction and relaxation of high-intensity exercise. Ca(2+) handling is altered by diabetes mellitus, but has not previously been investigated in human skeletal muscle. We investigated effects of high-intensity exercise
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service